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1This case study illustrates the benefits of 
taking a strategic approach to maximize 
a foundation’s impact. It describes how 
a foundation has narrowed its focus and 
assessed its performance.
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Less than a decade ago, Arizona’s Flinn Foundation 
began implementing a strategy that focused on boost-
ing its state’s bioscience economy and relied heavily on 
building collaborative partnerships. Since that time, 
Arizona has seen dramatic increases in jobs, research 
funding, businesses, and wages within the bioscience 
sector. According to Martin Shultz, vice president of  
Pinnacle West Capital, the state’s largest utility, Flinn’s 
strategic and collaborative effort to build Arizona’s 
bioscience infrastructure has changed the landscape. 
“There was little here before,” he says, “and now we 
have in Arizona many, many examples of  new bio-
medical discoveries – many of  which have been FDA 
approved and are in the market.”
Flinn’s journey began with a belief  that the Founda-
tion could play a distinctive role in improving health-
care. According to Flinn’s president and CEO John W. 
Murphy, “One of  the reasons for investing in biosci-
ence is that you want to be able to apply laboratory 
discoveries to patients more effi ciently and effectively.” 
To fulfi ll that vision, Flinn tightened its focus, defi ned 
specifi c goals, and created metrics to measure its 
progress along the way. 
Flinn’s evolution to becoming more strategic has 
not been without its challenges. Murphy describes 
the process of  revisiting the mission as “painful,” and 
the change in focus resulted in some tough discus-
sions with grantees and staff. While the new strategy 
appears to have contributed to positive results for 
Arizona, some criticize the Foundation’s choices, its 
communications, and what they see as overly-ambi-
tious – and even unrealistic – goals.
Hard Questions Lead 
to Change
When Murphy joined the Foundation in 1981, it was 
focusing its grants on advancing medical education, 
biomedical research, and a few community health 
projects. A few years into Murphy’s tenure, sparked 
in part by donor bequests that doubled its assets and 
made Flinn the state’s largest philanthropic funder at 
the time, the Foundation expanded its focus to sup-
port programs in education and the arts. By 2001, the 
Foundation was managing a portfolio of  100 to 150 
grants per year in a wide range of  areas that included 
programs for pregnant teenagers, projects addressing 
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arships, and endowed chairs. “It was classic mission 
drift,” says Murphy. 
Several factors contributed to Flinn’s decision to 
change its approach. First, the Foundation was un-
dergoing a transition in the composition of  its board. 
“New members were asking fundamental questions 
about how you forge a cohesive grant program that will 
do justice to the intent of  the donors,” says Murphy, 
a former university administrator who came to Flinn 
from the Robert Wood Johnson Foundation. These 
questions launched an open dialogue with more expe-
rienced board members about the history and purpose 
of  the Foundation.
Another factor that led Flinn’s leadership to question 
its activities was the heavy criticism aimed at some of  
the projects it was funding. “We were risk takers. But 
you don’t want to ignore the criticism. You want to 
examine it and then say, ‘we’ll keep moving on or we 
won’t,’” says Murphy. While the Foundation didn’t 
back down from funding controversial programs – for 
example, a program that helped pregnant teenagers 
fi nish high school – the criticisms did push its leaders 
to take a hard look at whether the projects they had 
funded were likely to be self-sustaining and whether 
the Foundation was making the most effective use of  
its grant funds.
 “The projects we’d funded had worked well, and 
we’d published some good materials that people were 
“WE BEGAN ASKING OURSELVES 
FUNDAMENTAL QUESTIONS. WHAT’S 
THE INTENT HERE? HOW DOES THIS 
ALL FIT TOGETHER? GIVEN OUR LIMITED 
RESOURCES, HOW MANY NEW PROJECTS 
PER YEAR CAN FLINN DO?”
using,” says Flinn’s current board chair, David Gul-
len, M.D. “But they didn’t seem to have any legs. It 
seemed like the only way they could continue was if  
we kept funding them. We began asking ourselves, 
‘How do you move teen pregnancy? How do you 
move research?’” 
At the same time as Flinn’s leadership was reexam-
ining the Foundation’s approach to its mission, Arizo-
na was facing an economic downturn. And although 
people often view Arizona as a retirement state, “Its 
median age is among the younger of  the states,” notes 
Murphy. “So we’re attracting young people who are 
seeking careers and jobs.” With the economic base in 
peril and an infl ux of  new people, the state was facing 
enormous infrastructure needs, such as more schools, 
hospitals, highways, and parks, just to keep up with the 
population growth. 
The state’s economic outlook, coupled with an emer-
gence of  new foundations in Arizona that had greater 
wealth than Flinn and that were funding in similar 
areas, opened up a new opportunity for the Founda-
tion. “We began asking ourselves fundamental ques-
tions,” says Murphy. “‘What’s the intent here? How 
does this all fi t together? Given our limited resources, 
how many new projects per year can Flinn do? As we 
looked at the environmental assessment of  what was 
happening around and within our state as well as what 
was happening in health care, in concert with review-
ing our donors’ intent, we began to realize that there 
was a special niche for this Foundation.” 
Solidifying a Direction 
for Change
Flinn’s leaders took several steps toward adopting a 
more strategic approach. First, they revisited Flinn’s 
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revealed that each board member had a different view 
of  what the foundation was doing. “It’s painful because 
you think you know your organization very well, and 
then you fi nd that with 15 people in the room you’ve 
got 15 different answers,” says Murphy. Yet, he con-
tinues, “When you looked at what Dr. and Mrs. Flinn 
did during their lifetimes in steering this organization, 
it was primarily in the biomedical sector. So when we 
scraped back to the raw bone and asked, ‘What is it we 
are about, what’s the charge here, what’s the most ef-
fective use of  the funds they committed?’ we realized 
that improving life in Arizona is about future genera-
tions and that the foundation’s money is meant to be 
engaged in applying resources for long-term systemic 
changes and not for short-term charitable goals. Those 
are two key elements that were linked in our minds as a 
starting point.” 
Once the decision was made to focus the Foundation’s 
work more tightly, Flinn’s Board of  Directors identifi ed 
three broad areas for exploration: health policy, com-
munity health, and bioscience research. The Board then 
asked the staff  and a team of  consultants to develop a 
scenario for translating each of  those areas into action 
plans. After considering all three the Board chose to fo-
cus on the biosciences. “While some of  them may have 
favored a different scenario, none of  them wanted to 
return to the broad-brush approach,” says Murphy. “So 
while it took a while for some who did not favor this 
approach to embrace it, there’s not a one of  them now 
who would second-guess that decision.” 
With its area of  focus nailed down, the Founda-
tion hired Battelle, a national consulting fi rm to as-
sess biomedical research in Arizona. “They identifi ed 
Arizona’s strengths and weaknesses and benchmarked 
us against other states,” says William S. Read, PhD, 
Flinn’s senior vice president of  Special Research and 
Programs. The study launched the state’s “Bioscience 
Roadmap,” a 10-year plan to fast track Arizona on a 
path to achieve national bioscience stature and a di-
versifi ed economy. 
Setting Goals and Defining 
Metrics
The Roadmap set several goals to help make Arizo-
na competitive in biotechnology within 10 years (by 
2012). These include the following:
Build research infrastructure• 
Build critical mass of  fi rms• 
Enhance business environment• 
Prepare workforce, educate citizens• 
To ensure progress on these goals, Flinn asked the 
consulting team to identify specifi c strategies for each 
and develop a set of  metrics to help assess the effective-
ness of  those strategies. The primary measures are
The rate of  growth in National Institutes of  • 
Health (NIH) grants
The creation of  new high-paying jobs in the • 
biotech sector
The growth and/or expansion of  biotech • 
companies, and 
The commitment of  public and private re-• 
sources within Arizona to the bioscience sector 
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approach,” says Murphy. “We won’t make as many 
grant commitments, but those we do make will be far 
more signifi cant in terms of  impact on recipients, and 
also more fundamental to that organization because 
the funds are used more fl exibly to build institutions 
rather than on a conventional narrow project for a 
few years.” In fact, Flinn now awards only about fi ve 
grants per year. “That’s probably the most quantifi -
able expression of  this change,” says Murphy. 
Because Flinn is making fewer grants, those it does 
make are larger, longer-term, and support multidisci-
plinary, collaborative efforts involving research teams 
at the state’s public universities and nonprofi t research 
institutions. Furthermore, Flinn leverages its grant dol-
lars, making commitments by providing either match-
ing or challenge grants or by mak-
ing grants that are large enough to 
attract the interest of  others who 
could add value to the project. 
Flinn’s strategic approach doesn’t 
end with grantmaking. The Foun-
dation uses other resources besides 
its grant dollars to achieve its goals. 
“To carry all this out, you need a 
broad coalition and a champion. 
And, like it or not, Flinn has be-
come Arizona’s bioscience cham-
pion,” says Murphy. “To be the 
champion is to be an advocate and 
leader. A lot of  what we do revolves 
around being a source of  reliable 
information and data to the media, 
legislators, research scientists, and 
others who also want to champion 
projects and initiatives within the 
bioscience arena.” 
“We did not see the Roadmap as static,” says Mur-
phy. “We took steps to ensure that this was not just 
another report stored on some shelf  somewhere. We 
involved more than 300 leaders throughout the state 
to offer their ideas and suggest comparative measures. 
Plus, Flinn leadership stayed involved in every aspect 
of  mapping how those goals were to be achieved, con-
vening groups, gathering and sharing data, involving 
consultants. We also built in an annual progress report 
card that is independently compiled.”
Implementing the Change
Within the Roadmap, Flinn focused its grants on 
building research infrastructure and nurturing a thriv-
Mission:
To improve the quality of life in Arizona to 
benefi t future generations.
Strategy One: 
Build
Partner with Ari-
zona’s universities, 
research institutions, 
industry, and other 
funders to build a 
collaborative re-
search infrastructure.
Strategy Two: 
Translate
Identify and  invest 
in signature  projects 
to facilitate the 
application of 
new discoveries to 
clinical medicine 
and personalized 
patient care.
Strategy Three: Champion
Promote awareness of Arizona’s bioscience enterprise 
by providing timely, factual information and counsel.
Vision
We envision Arizona as a 
global center for research 
and commercialization 
in the biosciences.
5“IF YOU ARE GOING TO DO COLLABORATIVE PROJECTS, 
BRING PEOPLE ON BOARD DURING THE PLANNING 
STAGES BECAUSE THEN YOU’VE GOT TERRIFIC BUY-IN. 
YOU’VE GOT A SALES FORCE OF ADVOCATES. IT IS A 
GROUP PROJECT – NOT JUST FLINN’S PROJECT.”
Testing the Strategy
While Flinn’s leadership was working through the 
change, and outsiders were not yet aware of  it, a ser-
endipitous request gave its new direction a jumpstart. 
The Foundation was asked to help start a research 
institute based on the human genome project. Flinn 
convened a group of  leaders from the corporate and 
academic sectors to consider collectively whether the 
project was feasible and how the group could ultimate-
ly secure the monies needed for the project. 
“The project provided an immediate external ex-
pression of  our internal conclusions,” says Murphy. 
“Nearly $100 million was required, and we quickly re-
alized that a mix of  private- and public-sector funding 
would be needed. Being in the forefront of  that effort 
enabled us to earn our spurs right away. It is a won-
derful example of  how to build a coalition quickly,” 
he says. “Having an established trust relationship with 
key decisionmakers is critically important.”
Today the Translational Genomics Research Insti-
tute (TGen), a Flinn grantee, is a free-standing re-
search institute with formal partnerships between the 
Arizona Board of  Regents and universities.  Its reach 
is global: TGen recently announced a $200 million 
partnership with Luxembourg, and another with Sin-
gapore is pending. 
Partnering for Greater Impact
With a staff  of  17 and an endowment of  just over $215 
million, Flinn made building collaborative partnerships 
to fund research infrastructure not only a crucial fi rst 
step, but a key component of  its strategy to develop Ari-
zona’s biosciences. “Because we are a small foundation,” 
says Read, “it is unrealistic to think 
that we could, on our own, make the 
kinds of  investments that creating 
a bioscience research infrastructure 
in Arizona demands. We must con-
vince other funding partners, public 
and private, to also invest in those 
research infrastructures.”
According to Gullen, it is important to bring in part-
ners as early as possible. “If  you are going to do col-
laborative projects, bring people on board during the 
planning stages because then you’ve got terrifi c buy-in. 
You’ve got a sales force of  advocates. It is a group proj-
ect – not just Flinn’s project,” he says. He does offer one 
caveat, however. “When you go in with partners, you’ve 
got to be willing to give up a little bit of  control.”
It also meant altering the Foundation’s working cul-
ture. “We took on some of  the characteristics of  an oper-
ating foundation,” Murphy says, “convening numerous 
groups, hiring specialist consultants to assist govern-
ment leaders, and implementing the Roadmap.”
Communicating the Strategy
Attracting others to the cause required a tightly 
planned, well-organized communications effort and 
Flinn’s leadership beefed up its communications staff  
to aid in that endeavor. The team was led by Execu-
tive Vice President Saundra Johnson, an experienced 
6health care executive with a background in strategic 
planning and collaboration building, who was respon-
sible for designing the strategy implementation.
The communications team’s fi rst step was to revise 
the messaging in Flinn’s already existing publications, 
such as the annual report, to refl ect its new direction. 
What was once a traditional Web site that focused on 
the Foundation’s history, staff, and activities evolved 
into a resource providing the latest information about 
biosciences in Arizona. Web content now includes 
electronic newsletters, blogs on external research op-
portunities, digests of  bioscience news developments, 
a meetings calendar, and an industry directory. 
To introduce people to the Roadmap concept, Flinn 
hosted presentations in three cities. “In Phoenix, we 
had the governor and governor-elect speak, as well as 
the mayor of  Phoenix,” says Johnson. “And then we 
drove to Tucson and had a luncheon with the same 
kind of  high-level community leadership presence.” 
The Foundation then did the same thing in Flagstaff  
at the northern end of  the state.
 “This is similar to doing a grassroots political cam-
paign,” says Johnson. “You fi gure out how to com-
municate with different groups and identify the key 
leaders who can carry your message to those groups. 
And that’s basically what we did. We put a solid com-
munications plan in place, did presentations, met with 
people around the state, and started to develop the 
relationships, understanding, and enthusiasm to ad-
vance the biosciences.”
To hone its messaging, Flinn’s communications team 
met with a variety of  groups, including those work-
ing in industry, hospital PR, at the universities, and 
in government. “We took them through a facilitated 
process to learn what they thought the most important 
messages were to communicate the importance of  the 
biosciences,” says Johnson. The result was a working 
document of  messages that were broken down by con-
stituencies. “For example, in conversations with leg-
islators, information important to the economy, job 
growth, and education requirements were stressed. 
However, if  you were addressing scientists, more tech-
nical messaging was developed, ” she explains. 
To help deliver those messages, Flinn created the 
Arizona Bioscience Roadmap Steering Committee, 
which includes state legislators and other government 
offi cials, an array of  business leaders, researchers, and 
university executives. “We started with 28 members, 
and we’ve grown to 80,” says Johnson. “It’s a great way 
to get the word out and keep people engaged.” Steer-
ing Committee members participate in work groups 
focused on issues related to the biosciences, such as 
development of  venture capital, education, workforce 
development, and research.  
Flinn also provides a yearly opportunity for steering 
committee members to meet with the state’s congres-
sional delegation in Washington, D.C. “We do it as an 
educational opportunity,” says Johnson. “It reminds the 
[congressional] staff  that bioscience activity is important 
in Arizona. It also brings in key corporate and civic lead-
ers that the delegation may see at other times on other 
business, but that they wouldn’t necessarily associate 
with this effort. Our collective presence helps them un-
derstand the breadth of  the collaboration and provides 
specifi cs about what is currently happening in Arizona.” 
“THIS IS SIMILAR TO DOING A 
GRASSROOTS POLITICAL CAMPAIGN. YOU 
FIGURE OUT HOW TO COMMUNICATE 
WITH DIFFERENT GROUPS AND IDENTIFY 
THE KEY LEADERS WHO CAN CARRY YOUR 
MESSAGE TO THOSE GROUPS.”
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grantees so that they could use the challenge to get new 
dollars,” Read says. The new funders in the state also 
helped lessen the blow to grantees because they worked 
in areas that once had been traditional grant focuses for 
Flinn and so became fresh sources of  funding. 
Close, trusting relationships with grantees also 
proved to be an asset in creating a smooth transition, 
says Read. “Over the years we had developed a lot 
of  good will with our grantees because of  our his-
tory of  not only providing them with grant money but 
also providing them with consulting expertise, techni-
cal assistance, and help in finding additional funding 
from other sources,” he says.  
Role of the Board 
As Flinn’s activities changed in response to the new 
strategy, so too did those of  its Board. For one thing, 
rather than review and authorize a diverse stack of  
new grant requests, board members can now delve 
more deeply into key aspects of  the critical infrastruc-
ture organizations Flinn funds. “They hold meetings 
at grantee sites, have frequent scientifi c presentations 
by key leaders, and are briefed by key community and 
legislative leaders. They’ve become more knowledge-
able about community issues and the dynamics of  ed-
ucational and research organizations, especially start-
up organizations,” says Murphy.
 The Board also takes a more holistic view of  the 
Foundation’s work. “The Board now thinks of  total 
resource allocation rather than just grants in one cat-
egory and investments in another,” he says. “For ex-
ample, to jumpstart local venture capital investments 
in the biosciences, our Board has earmarked a portion 
of  our investment portfolio to be used for Arizona bio-
Side Effects of Change
The new approach didn’t just keep the communi-
cations team busy, it also changed the substance of  
the program staff ’s daily work. According to Read, 
it meant “leaving areas such as policy and access to 
health care in which the Foundation was highly effec-
tive, and in which staff  both liked working and were 
highly profi cient.” 
Furthermore, the new focus demanded that Flinn’s 
staff  – the majority of  whom are generalists with pro-
fessional backgrounds – become profi cient in the new 
area of  focus. “We’ve had to retool ourselves as we go 
along,” says Read. He points to his own experience as 
an example, “I’m trained as a cultural anthropologist 
and medical sociologist. With this change to biomedi-
cal research, I’ve had to learn about commercializa-
tion, for example.” 
Staff  also became engaged in national biomedical 
research organizations and networked with and joined 
economic development groups to gain a better under-
standing of  those issues for the state, and to represent 
the strategies of  Arizona’s Biosciences Roadmap.
One painful aspect of  implementing the strategy – 
for both board and staff  – was the need to say goodbye 
to grantees as the Foundation discontinued programs 
that did not fi t into its new focus. As a fi rst step, the 
Foundation canceled planned new initiatives, made a 
few transition grants, and gently closed the door on 
former grantees. “There was a period of  about three 
years when we continued to honor our commitments 
to help the organizations transition themselves to other 
sources of  funding,” says Read. “Several of  the proj-
ects that we funded prior to adopting our more narrow 
focus are still ongoing,” he says.
Program staff  worked closely with grantees to cre-
ate a soft landing for those that would not be part of  
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science start-up projects. We’ve made a few key invest-
ments that have generated good returns already.” 
According to Gullen, the Board receives updates on 
and discusses the Roadmap at every meeting, focusing 
on specifi c areas. For instance, he says, “We’ve made 
a lot of  progress in biomedical research though we’re 
not fi nished by any means. But one area that seems to 
be lagging a bit is venture capital – getting capital in 
the state to take discoveries to commercial value. So 
we spend a lot of  time thinking about that and discuss-
ing different strategies that we could use.” 
Reporting Progress
Flinn’s Board is able to stay abreast of  its progress in 
implementing the Roadmap because the Foundation 
closely monitors how well the strategy is working. In 
addition to developing metrics to assess progress on 
each of  its goals, its consulting team updates those 
metrics annually. 
Flinn informs stakeholders about their progress 
through regular presentations, and it posts quarterly 
progress reports on its Web site (www.fl inn.org). Its lat-
est report, released in January 2009, documents results 
for the Roadmap’s metrics of  success. 
Between 2002 and 2007 
NIH funding increased 24 percent in Ari-• 
zona, with its performance outpacing the top 
10 states (up 11 percent) and the U.S. (up 11 
percent).
Biotechnology jobs increased by 23 percent • 
(nearly 16,000 jobs), exceeding growth in the 
U.S. as a whole.
Trends in federal research grants (2002–2007)
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9the Center for Effective Philanthropy’s Stakeholder 
Assessment Report (STAR), which uncovers the per-
ceptions of  stakeholders on a range of  topics – from 
the Foundation’s communications and resources to its 
infl uence and impact. 
The STAR revealed some challenges that the Foun-
dation must address if  it is to maximize its impact. For 
example, even though Flinn has a well-planned com-
munications program, nearly half  of  its stakeholders 
rate their understanding of  Flinn’s goals less than a 6 
or 7 on a 1 to 7 scale. Furthermore, stakeholders who 
rate Flinn less highly in its effectiveness in accomplish-
ing its goals often cite their lack of  information as a 
reason for the lower rating. 
In addition, many stakeholders believe that Flinn 
has over-reached in its goals – especially the goal of  
translating research discoveries into patient care and 
commercial opportunities. When asked how effec-
tive the Foundation is at accomplishing this goal, the 
Biotechnology fi rms increased by 22 percent. • 
(Medical devices, research, testing, and medi-
cal labs are key segments.)
Biotechnology wages increased 34 percent, • 
with the average salary at $52.5K. (Arizona 
bioscience workers earned $11,000 per year 
more than workers in the overall state private 
sector in 2007.)
Indicators covering 2002 – 2008 show
Start-ups up 50 percent (42 biotech startups).• 
Licenses up 15 percent (176 biotech licenses).• 
Not all the news is positive, however. 
Risk capital is down 41 percent having • 
reached 86 percent of  the goal in 2007 and 
65 percent of  the goal in 2008.
Biotech income is down 18 percent – a total • 
of  $14.4m with a signifi cant decline in 2008 
over 2006 – 2007 levels. 
Still, the data suggests that Flinn is making an impact 
with the work it is doing along with others in the state. 
TGen’s President and Chief  Scientist, Dr. Jeffrey Trent, 
is impressed by Flinn’s track record of  investigating rel-
evant data, setting milestones, and using third parties to 
assess its performance. “They are a unique resource to 
the state,” he says. “They are viewed as a trusted source 
of  information. They are a best-practice example of  
how making targeted investments and having a directed 
mission can play a critical role. We are evidence of  the 
impact they have had on Arizona’s biosciences.”
To meet its goals, Flinn must also continue to engage 
stakeholders from a variety of  disciplines. Flinn re-
cently surveyed more than 200 Arizona leaders using 
“How clearly do you understand 
the Foundation’s current goals?”
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average rating was a 4.4 on a scale of  1 to 7 where 
1 is not at all effective and 7 is very effective. “I am 
not sure that the Flinn Foundation understands how 
to translate discoveries into patient care and commer-
cialization,” commented one stakeholder. “Commer-
cial activities are a big challenge that go beyond Flinn, 
despite Flinn’s laudable efforts,” wrote another.
The diverse stakeholder groups also pose another chal-
lenge. While the majority thinks that Flinn has chosen 
appropriate goals, their perceptions of  which activities 
are most important in achieving those goals vary from 
one stakeholder community to another. “Satisfying these 
diverse opinions will require some careful balancing in 
the years to come,” says Read. “Researchers and health 
care providers have different priorities, and educators 
would favor stronger math and science programs in the 
schools as a priority. We really need to keep everybody 
at the table. We will be successful in accomplishing our 
goals only if  we can continue to foster and maintain these 
important partnerships.”
Overall, however, stakeholders describe Flinn in 
positive terms, according to the CEP report, and the 
majority mentions the Foundation’s leadership and 
the quality of  its staff  as strengths.
Shultz, the utility executive, who also chairs Ari-
zona’s Bioscience Roadmap Steering Committee, be-
lieves that Flinn has made an important difference in 
the state by charting the Roadmap. “They’ve literally 
changed the landscape and the approach. We set the 
goals to grow the industry and that’s exactly what 
we’re doing. I don’t know if  we would have attracted 
this many venture capitalists, or this much money or 
interest in this general industry, had we not had the 
Roadmap as a framework.” 
Moving Ahead
Flinn’s leaders say that although the Foundation is at 
the midpoint in terms of  fulfi lling the goals it set out 
in 2001, they expect the current economic downturn 
to slow their progress. 
Read predicts that it will take Flinn longer than hoped 
to reach some key goals. “The Board is very comfort-
able with what we’re doing. Like us, they realize that an 
economic downturn like this can be an enormous op-
portunity to rearrange the deck chairs so they can catch 
even more sunlight. There are opportunities, but we 
have to become even more astute about what’s happen-
ing in our environment and how to proceed and how 
leadership in the state wants to do that.”
In the meantime, Flinn will continue to address the 
challenges of  positioning and improving Arizona’s re-
search infrastructure to keep pace with the global en-
vironment. “It’s all about overall effectiveness,” says 
Murphy. “If  foundations want to leverage their grant 
dollars to the greatest degree possible, taking a strate-
gic approach can generate lasting impact.”
Judith A. Ross is senior research writer for CEP.
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About the Center for 
Effective Philanthropy
The Center for Effective Philanthropy (CEP) is a 
nonprofi t organization focused on the development 
of  comparative data to enable higher-performing 
foundations. CEP’s mission is to provide data and create 
insight so philanthropic funders can better defi ne, assess, 
and improve their effectiveness and impact. 
 This mission is based on a vision of  a world in which 
pressing social needs are more effectively addressed. It 
stems from a belief  that improved performance of  funders 
can have a profoundly positive impact on nonprofi t 
organizations and those they serve. 
 CEP pursues its mission through data collection and 
research that fuel the creation of  research publications, 
assessment tools, and programming. 
Research
Since receiving initial funding in 2001, CEP has produced 
widely referenced research reports on foundation strategy, 
performance assessment, foundation governance, and 
foundation – grantee relationships. CEP has created new 
data sets relevant to foundation leaders and provided 
insights on key issues related to foundation effectiveness. 
All of  CEP’s reports can be downloaded or ordered on 
our Web site. 
Assessment Tools
CEP has developed widely used assessment tools 
such as the Grantee Perception Report® (GPR), 
Applicant Perception Report (APR), Comparative 
Board Report (CBR), Staff  Perception Report 
(SPR), Stakeholder Assessment Report (STAR), and 
Multidimensional Assessment Report (MAP). Nearly 
200 foundations have used CEP’s assessment tools – 
most implementing signifi cant changes on the basis of  
what they have learned. 
Copyright 2009, The Center for Effective Philanthropy, Inc. All rights reserved. 
Programming
CEP offers programming for foundation trustees, CEOs, 
senior executives, and trustees. CEP’s programming 
features our latest research and highlights exemplars 
in the fi eld. Conferences are candid, hard-hitting, and 
practical, bringing foundation leaders together to learn 
from each other and set a higher standard for foundation 
performance. Conferences feature sessions on strategy 
development, performance assessment, governance, 
and leadership. 
For more information on CEP, and to download or order our reports, 
please visit www.effectivephilanthropy.org.
Other Case Studies 
Improving the Grantee Experience at the David and Lucile Packard 
Foundation (January 2008) describes how leaders at 
Packard identifi ed and translated the elements of  quality 
interactions and clear communications with grantees 
into specifi c criteria. The case study explores how 
they developed and implemented these criteria, called 
Grantee Experience Standards, as a way to strengthen 
the Foundation’s relationships with its grantees.
 Aiming for Excellence at The Wallace Foundation (June 
2008) describes how leaders at Wallace have responded 
to results of  the Grantee Perception Report® (GPR), 
which the Foundation has repeated three times. Each 
successive GPR has enabled foundation leaders to 
more sharply hone their performance improvement 
efforts as they embark on a series of  actions. The case 
study highlights a foundation working to improve its 
performance in response to comparative assessment 
data, illustrating the need for continuous feedback loops 
to inform decision-making.
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